The Administrative Core, directed by Dr. Hagop Kantarjian, provides critical centralized administrative support to ensure the success of the entire SPORE. The specific objectives of the Administrative Core are: Oversee all SPORE activities, in particular the research activities Promote integration and communication between the SPORE, the Leukemia Program, and the Cancer Center Support (Core) Grant Ensure compliance with institutional, governmental, and NCI regulations Assume responsibility for coinmunications and consultations with the NCI project officer and other NCI staff to ensure timely preparation and submission of reports and publications Oversee the fiscal and budgetary activities of the SPORE Coordinate data control quality assurance issues in conjunction with the Internal Scientific Advisory Committee and the Biostatistics and Data Management Core (Core C) Coordinate activities associated with clinical trials, e.g., designs, approval by regulatory bodies, implementation, and eligibility and assignment of patients to different studies Provide oversight and support for the Biostatistics and Data Management Core (Core C) and the Pathology and Tissue Core (Core B) Coordinate meetings of the [Executive Committee, the Internal and External Scientific Advisory Committees, monthly investigator meetings, quarterly research meetings, lectures, and symposia Administer the Developmental Research Program and the Career Development Program Administer the activities of the Patient Advocates Ensure compliance with and improvement of policies for recruitment of women and minorities Coordinate with other Leukemia SPORE programs and investigators, and other organ-site SPORE programs, to promote communications and integration, through sponsoring a yearly SPORE conference, and distribute materials, electronic communications and progress reports Organize seminars to bring to M. D. Anderson consultants and speakers;sponsor a yearly conference on Translational Research in Leukemia

Public Health Relevance

(See InstrLctions): The Administrative Core provides the support and infrastructure for research and financial oversight;clear and open communications among all SPORE investigators, patient advocates, and developmental awardees;and regulatory monitoring to optimize the successful outcome of the translational research in leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-11
Application #
8499751
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2013-05-01
Project End
2018-08-31
Budget Start
2013-09-13
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$102,484
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Johanning, Gary L; Malouf, Gabriel G; Zheng, Xiaofeng et al. (2017) Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci Rep 7:41960
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Kanagal-Shamanna, Rashmi; Loghavi, Sanam; DiNardo, Courtney D et al. (2017) Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102:1661-1670
Katerndahl, Casey D S; Heltemes-Harris, Lynn M; Willette, Mark J L et al. (2017) Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 18:694-704
Kelly, A D; Kroeger, H; Yamazaki, J et al. (2017) A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia 31:2011-2019
Mu, Yunxiang; Zelazowska, Monika A; McBride, Kevin M (2017) Phosphorylation promotes activation-induced cytidine deaminase activity at the Myc oncogene. J Exp Med 214:3543-3552
Pratz, Keith W; Levis, Mark (2017) How I treat FLT3-mutated AML. Blood 129:565-571
Nieborowska-Skorska, Margaret; Sullivan, Katherine; Dasgupta, Yashodhara et al. (2017) Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest 127:2392-2406
Kayser, Sabine; Levis, Mark J (2017) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol :
Kerros, Celine; Tripathi, Satyendra C; Zha, Dongxing et al. (2017) Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292:10295-10305

Showing the most recent 10 out of 450 publications